Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “AChR Myasthenia Gravis”

19 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 19 results

Not applicableLooking for participantsNCT06967480
What this trial is testing

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Who this might be right for
Generalized Myasthenia GravisAnti-AChR Antibody Positive
Alexion Pharmaceuticals, Inc. 40
Post-approval studies (Phase 4)Looking for participantsNCT06860633
What this trial is testing

Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod

Who this might be right for
Myasthenia Gravis CrisisMyasthenia Gravis ExacerbationsAChR Myasthenia Gravis
University of Colorado, Denver 20
Large-scale testing (Phase 3)Looking for participantsNCT06463587
What this trial is testing

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Who this might be right for
Generalized Myasthenia Gravis
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany 264
Large-scale testing (Phase 3)Looking for participantsNCT06607627
What this trial is testing

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

Who this might be right for
Generalized Myasthenia GravisgMG
Alexion Pharmaceuticals, Inc. 12
Large-scale testing (Phase 3)Study completedNCT03304054
What this trial is testing

Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

Who this might be right for
Myasthenia Gravis, Generalized
Catalyst Pharmaceuticals, Inc. 93
Not applicableLooking for participantsNCT07247279
What this trial is testing

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

Who this might be right for
Rare DiseasesGeneralized Myasthenia Gravis (gMG)
AstraZeneca 450
Large-scale testing (Phase 3)Active Not RecruitingNCT05556096
What this trial is testing

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

Who this might be right for
Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc. 261
Not applicableStudy completedNCT05219097
What this trial is testing

The Specificity, Sensitivity and Clinical Correlation of CBA, RIPA and ELISA in Detecting AChR and MuSK IgG of Myasthenia Gravis

Who this might be right for
Detection Autoantibody of Myasthenia Gravis
Tianjin Medical University General Hospital 2,663
Testing effectiveness (Phase 2)Ended earlyNCT04226170
What this trial is testing

Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis

Who this might be right for
Myasthenia Gravis
DAS-MG, Inc 2
Large-scale testing (Phase 3)Looking for participantsNCT06517758
What this trial is testing

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG.

Who this might be right for
Generalized Myasthenia Gravis
Novartis Pharmaceuticals 146
Not applicableLooking for participantsNCT07294170
What this trial is testing

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Who this might be right for
Myasthenia GravisMGgMG+3 more
argenx 70
Testing effectiveness (Phase 2)Looking for participantsNCT07284420
What this trial is testing

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Who this might be right for
AChR-Ab Seropositive Generalized Myasthenia GravisMyasthenia GravisMG+3 more
argenx 70
Testing effectiveness (Phase 2)Looking for participantsNCT06359041
What this trial is testing

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Who this might be right for
Generalized Myasthenia Gravis (gMG)
Cabaletta Bio 12
Large-scale testing (Phase 3)Looking for participantsNCT05868837
What this trial is testing

Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)

Who this might be right for
Myasthenia Gravis, Generalized
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 40
Not applicableActive Not RecruitingNCT07071246
What this trial is testing

Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis

Who this might be right for
Treatment
Tang-Du Hospital 30
Large-scale testing (Phase 3)Ended earlyNCT03579966
What this trial is testing

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

Who this might be right for
Myasthenia Gravis, MuSKAChR Myasthenia Gravis
Catalyst Pharmaceuticals, Inc. 63
Testing effectiveness (Phase 2)Looking for participantsNCT06414954
What this trial is testing

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

Who this might be right for
Myasthenia GravisMyasthenia Gravis, MuSK
NMD Pharma A/S 84
Not applicableLooking for participantsNCT06815133
What this trial is testing

Effectiveness and Safety of Zilucoplan Treatment for French Patients With Myasthenia Gravis Over 3 Months

Who this might be right for
Myasthenia Gravis
Centre Hospitalier Universitaire de Nice 55
Testing effectiveness (Phase 2)Looking for participantsNCT06106672
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Who this might be right for
Myasthenia GravisGeneralized MyastheniaAChR Myasthenia Gravis+1 more
COUR Pharmaceutical Development Company, Inc. 54